Literature DB >> 19252513

Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP.

E Michael Lewiecki1.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19252513     DOI: 10.1038/ncprheum1024

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


× No keyword cloud information.
  5 in total

1.  National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.

Authors:  Nelson B Watts; E Michael Lewiecki; Paul D Miller; Sanford Baim
Journal:  J Clin Densitom       Date:  2008-06-18       Impact factor: 2.617

2.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.

Authors:  Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

Review 3.  Review of guidelines for bone mineral density testing and treatment of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

Review 4.  Osteoporosis prevention, diagnosis, and therapy.

Authors: 
Journal:  JAMA       Date:  2001-02-14       Impact factor: 56.272

5.  Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Robert Hopkins; Mary Ann Forciea; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-09-16       Impact factor: 25.391

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.